Iohexol is an iodinated contrast dye that has been shown to be useful in the estimation of glomerular filtration rate (GFR) in patients with suspected renal insufficiency. We developed and validated an ultraperformance liquid chromatography (UPLC)-triple quadrupole mass spectrometry (MS/MS) assay for quantifying iohexol in human serum.
Iohexol is an iodinated contrast dye that has been shown to be useful in the estimation of glomerular filtration rate (GFR) 2 in patients with suspected renal insufficiency (1 ). Iohexol is not bound to serum proteins and is filtered through the glomerulus, with no identifiable reabsorption or tubular secretion, making it an ideal marker for estimating GFR. Unlike other contrast agents such as iothalamate, iohexol has been reported to have a low allergenic potential.
Protocols have been developed that involve a single intravenous injection of iohexol followed by timed blood collections (2 ) . Iohexol clearance is then estimated using a 1-compartment model using data from the slow elimination phase (3 ) or a 2-compartment model that includes fast and slow elimination phase data (1 ) . No urine collection or quantification in urine is necessary.
Although serum or plasma iohexol can be measured using micellar electrokinetic capillary chromatography (4 ) or inductively coupled plasma atomicemission spectroscopy (5 ) , most published methods have used liquid chromatography-ultraviolet detection (LC-UV) (6 -10 ) , LC-MS (11 ), or LC-tandem mass spectrometry (LC-MS/MS) (12 ) with gradient elution profiles. Because of the high selectivity of mass spectrometry compared to ultraviolet detection, specimen cleanup is often simplified and shorter chromatographic times can be achieved. Ultraperformance liquid chromatography (UPLC), a recently introduced modification of LC, allows rapid chromatography owing to faster gradient curves, as well as the potential to use smaller particles and higher flow rates. We have combined these 2 techniques to develop a UPLC-MS/MS assay for iohexol in human serum. The assay uses a simple sample preparation, a structural analog internal standard with the same retention time, and a ballistic gradient for rapid chromatographic analysis.
Materials and Methods

CHEMICALS AND REAGENTS
We purchased iohexol and ioversol (certification of 100%) from US Pharmacopeia, formic acid (Fluka puriss grade) and zinc sulfate [American Chemical Society (ACS) grade] from Sigma-Aldrich, and acetonitrile and methanol (Optima grade) from Fisher Scientific.
PREPARATION OF SOLUTIONS
We prepared solutions of iohexol (10 g/L in water) for creating serum calibrators and controls from 2 separately weighed iohexol reference materials. Using these solutions, we prepared serum calibrators at concentrations of 50, 500, and 1500 mg/L and control sera at 100 and 1000 mg/L. We prepared a 1-g/L stock solution of the internal standard ioversol in methanol, which was further diluted in methanol to create a 20-mg/L working internal standard solution. Mobile phase A was 0.1% formic acid in water, and mobile phase B, 0.1% formic acid in acetonitrile.
SAMPLE PREPARATION
Using a Hamilton Microlab 500 diluter, we added 50 L calibrator, control, or patient serum and 400 L water into 1.5-mL conical polypropylene microfuge tubes. To this, we added 100 L of 0.25 mol/L zinc sulfate in water and 500 L working methanolic internal standard solution. The tubes were capped and vortex-mixed for 60 s. After centrifugation in a benchtop microcentrifuge for 4 min, we added 50 L supernatant to a labeled 1.5-mL glass autoinjector vial, followed by 1.0 mL water. The vials were capped, vortexmixed, and placed into sample trays for LC-MS/MS analysis.
LC-MS/MS
We performed UPLC-MS/MS using a Waters Acquity UPLC system connected to a Waters TQD tandem quadrupole mass spectrometer, operated in the electrospray positive ion mode with multiple reaction monitoring (MRM). A 5-L injection was routinely used, although imprecision was evaluated for 5-and 10-L injection volumes. Chromatography was achieved with a Waters Oasis HLB 5-m particle size, 2.1 ϫ 20 mm column maintained at 50°C. The flow rate was 0.4 mL/min. A programmed mobile-phase gradient was used during the 1.5 min run: 0 min, 0% B; 0.50 min, 0% B; 0.51 min, 20% B; 1.10 min, 20% B; 1.11 min, 100% B; 1.50 min, 100% B; 1.51 min, 0% B. We used a 0.5-min solvent/ divert delay to keep the electrospray probe and sample cone free from buildup of nonretained serum components and collected data beginning at 0.5 min. At the end of the run, the column eluant was again diverted to waste before the next injection. The MS/MS instrument and data collection parameters are shown in Table 1 . The MRM transitions used for integration and quantification were m/z 821.73803.7
) for ioversol in the electrospray positive ionization mode (Supplemental Figs. 1 and 2, which accompany the online version of this paper at www.clinchem.org/content/vol55/issue6). Quantification was performed using the QuanLynx function of MassLynx 4.1 software.
ASSAY VALIDATION
We determined extraction efficiency at serum concentrations of 100, 500, and 1000 mg/L (n ϭ 3). We compared the absolute response for iohexol diluted directly in water (no extraction) to the signal for extracted se- Point of origin Force rum diluted to the same final volume as described in the sample preparation protocol above. The percent extraction efficiency was calculated as (response extracted/response nonextracted) ϫ 100. We evaluated assay imprecision at iohexol concentrations of 10, 100, and 1000 mg/L. Intraassay and interassay imprecision were calculated from data obtained by analyzing sera in duplicate on 10 separate days. We also determined recovery at these 3 concentrations by comparing the measured iohexol concentrations against the nominal target concentrations.
We established linearity and lower limit of quantification (LLOQ) using published guidelines (13, 14 ) . We validated linearity (concentration-response relationship) using sera with concentrations of 2.5, 5.0, 10.0, 50, 100, 500, 1000, and 1500 mg/L. Acceptance criteria were 15% deviations of calibrators from nominal concentrations (20% at the LLOQ). The LLOQ was defined as the lowest concentration of iohexol that could be quantified with an imprecision Ͻ20% and a deviation from target Ͻ20%.
We investigated ion suppression using 5 serum pools, each pool containing serum from 3 individuals with increased serum creatinine concentrations. Additionally, we used 6 separate sera, including an icteric and slightly hemolysed sample, to evaluate matrix effect. Each pool or serum was extracted as described earlier and injected into the LC-MS/MS system along with concurrent postcolumn infusion of iohexol or ioversol before entering the electrospray probe (15) (16) (17) .
We evaluated postextraction stabilityby analyzing a series of calibrator, control, and patient sera extracts and then leaving the injection vials on the laboratory bench for a period of 24 h before reanalysis of the same vials by UPLC-MS/MS. Fig. 1 shows the chromatographic profiles for blank serum and serum containing iohexol and the internal standard ioversol. Both compounds had similar retention times of 0.96 min. Fig. 2 shows representative ion suppression profiles for an extract of a serum pool analyzed by UPLC-MS/MS. Any suppression effects occurred during the first 30 s of the chromatography and returned to full signal well before the elution times for iohexol or ioversol. We observed no ion suppression in any of the tested samples.
Results
We evaluated interference from 44 therapeutic drugs and contrast agents using a combination of standard solutions, control materials, or specimens from individuals being monitored after treatment (online Supplemental Table 1) . None of the compounds tested showed interference with either iohexol or ioversol.
(%) The mean extraction efficiencies (n ϭ 3) at iohexol concentrations of 100, 500, and 1000 mg/L were 100%, 100%, and 99%, respectively. Imprecision and recovery data for 5-and 10-L injection volumes are presented in Table 2 . The CVs at all 3 tested concentrations were within acceptance criteria, and the mean results were within 2% of the target concentration. For a 5-L injection and 2.5-mg/L concentration, the interassay imprecision CV (n ϭ 6) was 7.9% and the mean measured concentration was 2.7 mg/L (range Ϫ4% to 20% deviation from target). Because the CVs and mean concentration were within the accepted criteria, we set the LLOQ at 2.5 mg/L for a 5-L injection. For a set of specimen extracts left for 24 h on the laboratory bench, comparison of the peak area ratios yielded the following correlation: y ϭ 1.03x -0.05, R 2 ϭ 0.9986, where y ϭ the 24 h results and x ϭ the original results. The mean ratio of the 24-h calculated iohexol concentration to the original measured concentration was 1.00, with a median ratio (interquartile range) of 1.01 (0.96 -1.02). Both comparisons indicate acceptable stability of extracts if not analyzed immediately. Fig. 4 shows example 300-min clearance profiles (2, 18 ) for serum iohexol for 3 individuals with calculated GFR values of 132 mL/min/1.73m 2 , 109 mL/min/ 1.73m 2 , and 51 mL/min/1.73m 2 (institutional review board-approved use of patient data). These individuals received the same single dose of iohexol, and specimens 
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were collected at 5, 10, 15, 180, 240, and 300 min (2-compartment GFR). The lowest iohexol concentration at 5 h postinfusion that we have observed in patients tested to date is 18 mg/L, which is well above the 2.5 mg/L LLOQ for the assay. In patients with chronic renal failure, the measured 5-h serum iohexol concentrations are higher, and still Ͼ40 mg/L even at 12 h (12 ).
Discussion
Our initial goal was to validate a liquid chromatography method for the quantification of iohexol in serum that had a simple specimen cleanup and short chromatographic cycle times. Investigations of published HPLC-UV assays found that most of these assays were not optimal for our purposes because of required gradient chromatographic run times of 12-40 min, not including column reequilibration times. HPLC-UV assays also separate iohexol into 2 isomers, which requires selection of 1 isomer for calibration and quantification or the sum of 2 peak areas. Because we had instituted UPLC-MS/MS into our laboratory, we decided to use the speed and selectivity afforded by this technique toward iohexol analysis.
Two electrospray mass spectrometric methods have been described for the determination of iohexol. The LC-MS method of Denis et al. (11 ) was considered, but we were hesitant to employ the 180-min ultrafiltration step for sample cleanup and the apparent 17-min gradient separation used. We investigated the LC-MS/MS assay of Lee et al. (12 ) . Unfortunately, we discovered that the published chromatographic conditions for this assay did not work, since iohexol will not be retained on reversed-phase columns at the 30% organic solvent mobile phase reported for these authors' assay. Given the 2.1 by 100 mm column dimensions used in the assay, our calculations indicated that iohexol would elute at the solvent front (column void volume) and be poorly separated from other matrix components.
The retention of iohexol on reversed-phase columns requires an initial 100% aqueous mobile phase. After sample preparation, however, the solution in the injection vials contains approximately 2.3% organic solvent. Additionally, a 2.1 by 20 mm analytical column has only approximately 45 L fluid capacity. Therefore, because we observed no clear advantage to a 10-L injection volume, we chose to use a 5-L injection volume to minimize potential band broadening and split peaks (19, 20 ) . Ioversol was selected as the internal standard because it is very similar in structure to iohexol and has the same retention time, which theoretically should allow the internal standard to correct for minor electrospray ionization effects. During assay development and validation, we found that the use of 3 calibrators (50, 500, 1500 mg/L) plus the inclusion of a zero intercept in the quantification software was sufficient to obtain the imprecision and LLOQ data presented here. We retained the initial dilution of serum with water and the use of zinc sulfate/methanol for protein precipitation because we have previously observed a more homogeneous mixture as well as improved extraction efficiency for immunosuppressant drugs with this protocol (21 ) .
We chose the mobile-phase gradient described earlier for 3 reasons. First, when we tried a 30% acetonitrile or methanol initial mobile phase as described in the 1 other published LC-MS/MS assay (12 ), we were not successful in retaining iohexol and ioversol on several different C8 and C18 reversed-phase columns. Second, we desired enough retention on the analytical column to separate ion-suppressing components from the compounds of interest. Third, the 1-step weak gradient (20% acetonitrile) was sufficient to elute iohexol as a single peak (no isomer separation) and retain other less polar compounds until the brief 100% solvent wash.
Considering the polar nature of iohexol and ioversol, we selected the Waters Oasis HLB (hydrophiliclipophilic balance) sorbent because of the ability of the N-vinylpyrrolidone polymer to retain hydrophilic compounds. UPLC allows rapid gradient creation plus rapid reequilibration of analytical columns between injections. This allowed us to be conservative and retain the compounds of interest on the analytical column for 30 s, a time well beyond the ion suppression window, yet rapidly elute iohexol and ioversol within an additional 30 s.
The Acquity UPLC has a system dwell volume of approximately 100 L compared with 700 L for a standard HPLC system. As a result, changes in mobilephase composition such as programmed gradients require a much shorter time to reach the column. For example, with the same column, mobile-phase gradient, and flow rate, iohexol would have a retention time of 1 min with UPLC compared with 2.2 min with our Waters Alliance 2795 HPLC system, thereby consuming approximately one-half the volume of mobile phase. Similarly, column reequilibration can be achieved more rapidly, thereby allowing shorter analysis cycle times.
When using 100% aqueous mobile phases with many reversed-phase columns, a process known as "dewetting'" may occur (22 ) . Although the Oasis HLB column we selected has the design advantage of having water wettability, we observed that, between days, the chromatography and peak shape became optimal after 3 injection cycles. Our simple solution was to preequilibrate the column at the beginning of each run for 2 min with 50% mobile-phase B (acetonitrile), after which each sample injection demonstrated the desired sharp peak shape (Fig. 1) .
In summary, we have developed and validated a UPLC-MS/MS assay for quantifying iohexol in human serum. The assay uses 50 L sample and a straightforward protein precipitation protocol. Iohexol and the internal standard ioversol are captured and then eluted from a hydrophilic-lipophilic analytical column.
